TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

121 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweightHigh cholesterol

    Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

    Testing whether daily milk polar lipids affect heart and metabolic risk in adults with belly fat and

    📍 University of Connecticut · Storrs, CT · Get directions →

    The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

    ✓ Study care freeEarly Phase 1Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus

    📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →

    The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

    ✓ Study care freePhase 3Ages 40–70Learn more →
  • Multiple sclerosis (MS)

    Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    Testing a modified ublituximab treatment for relapsing multiple sclerosis

    📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →

    The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Obesity / overweight

    Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

    Testing a 52-week medicine versus placebo in adults with obstructive sleep apnea on CPAP

    📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →

    This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Obesity / overweight

    Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

    Testing whether obesity genes predict weight loss from a diet and a medicine

    📍 Columbia University Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Obesity / overweight

    Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

    Testing how added dietary fiber and metformin, alone or together, affect insulin resistance and

    📍 University of Alberta · Edmonton, Alberta · Get directions →

    This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.

    ✓ Study care freePhase 3Ages 12–18Learn more →
  • Obesity / overweight

    📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →

    This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Obesity / overweight

    Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

    Testing medicines plus lifestyle counseling to manage weight regain after bariatric surgery

    📍 University of California Irvine Medical Center · Orange, CA · Get directions →

    This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Obesity / overweight

    Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

    Testing a weekly under-the-skin injection to see effects on weight and diabetes markers

    📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →

    The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Obesity / overweight

    AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

    Testing a weekly under-the-skin medicine to help adults with obesity lose weight

    📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightType 2 diabetes

    A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

    Testing different doses of a medicine for weight loss in people with obesity or overweight and type

    📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →

    The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

    Testing an injection for brain scans to study Parkinson’s disease and safety

    📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →

    This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Obesity / overweight

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Testing whether setmelanotide improves weight loss, hunger, and life quality in children and adults

    📍 University of Alabama · Birmingham, AL · +7 more US sites · Get directions →

    This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO).

    ✓ Study care freePhase 3Ages 4+Learn more →
  • Parkinson's disease

    A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    Testing a Parkinson’s surgery approach to see if it is safe and works

    📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

    Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

    ✓ Study care freePhase 3Ages 45–75Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightType 2 diabetes

    A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

    Testing a medicine to see its safety and weight-loss effects in adults with obesity or overweight

    📍 CenExel Anaheim Clinical Trials · Anaheim, CA · +39 more US sites · Get directions →

    The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweight

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Testing safety and effectiveness of weight-loss medicines for kids with obesity

    📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +15 more US sites · Get directions →

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    ✓ Study care freePhase 3Ages 6–17Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Testing a drug called orelabrutinib versus placebo in people with PPMS

    📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Obesity / overweight

    Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.

    Testing if an IV medicine during bariatric surgery reduces pain and inflammation in adults with

    📍 Hospital de Especialidades Centro Medico Nacional Siglo XXI · Mexico City, Mexico City · Get directions →

    The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity. The main questions it aims to answer are: * Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?

    ✓ Study care freePhase 4Ages 18–60Learn more →
  • Obesity / overweight

    A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    Testing eloralintide in people with sleep apnea and obesity

    📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →

    The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweight

    DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

    Comparing HIV treatment medicines to see how they affect weight in people with obesity

    📍 Hospital de infectología, Centro Médico Nacional La Raza · Mexico City, · Get directions →

    Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.

    ✓ Study care freePhase 3Ages 18–55Learn more →
  • Obesity / overweight

    Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

    Testing a weekly shot to see if it is practical and helps weight in some postmenopausal breast

    📍 Weill Cornell Medicine · New York, NY · Get directions →

    This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Obesity / overweight

    A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    Testing whether eloralintide helps people with obesity or overweight and type 2 diabetes lose weight

    📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

    Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s

    📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →

    This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Obesity / overweight

    A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    Testing a medicine called eloralintide in adults with obesity or overweight without type 2 diabetes

    📍 MFA Clinical Research · Tuscaloosa, AL · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweight

    A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Testing tradipitant for nausea and vomiting from GLP-1 medicines in adults with obesity or

    📍 Vanda Investigational Site · Los Angeles, CA · +9 more US sites · Get directions →

    The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Entire-body PET Scans for Multiple Sclerosis

    Testing whether whole-body PET scans can better track MS brain and nerve damage

    📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →

    To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

    ✓ Study care freeEarly Phase 1Ages 25–55Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple

    📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Obesity / overweight

    📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →

    The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

    ✓ Study care freePhase 3Ages 10–17Learn more →
  • Obesity / overweight

    Induction of Labor in Morbidly Obese Patients

    Comparing different misoprostol doses to induce labor in people with severe obesity

    📍 University of Maryland Medical Center · Baltimore, MD · Get directions →

    The goal of this randomized control trial is to compare different doses of Misoprostol (25 mcg vs 50 mcg) in induction of labor (IOL) in morbidly obese patients with BMI \>40. It is known that morbid obesity is a risk factor for failed IOL and ultimately cesarean delivery (CD.) If the rates of vaginal delivery in this population can improve, then surgical morbidity can be reduced in these patients.

    ✓ Study care freeEarly Phase 1Ages 18+WomenLearn more →
  • Obesity / overweight

    Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

    Studying why fat tissue may respond differently in people with obesity

    📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →

    Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.

    ✓ Study care freeEarly Phase 1Ages 18–65Learn more →
  • Obesity / overweight

    A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    Testing a weekly injection medicine for adults with obesity and knee arthritis pain

    📍 Arizona Research Center, Inc. · Phoenix, AZ · +18 more US sites · Get directions →

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    18F-DOPA II - PET Imaging Optimization

    Testing an imaging scan to study Parkinson’s disease using PET

    📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →

    A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

    ✓ Study care freePhase 3Learn more →
  • Obesity / overweight

    L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation

    Testing whether a probiotic helps improve gut health and inflammation in people with obesity

    📍 University of Connecticut, Department of Nutritional Sciences · Storrs, CT · Get directions →

    This is a pilot research study to investigate the effects of a probiotic supplement (L. acidophilus, strain TW01) on substances found in the stool and bloodstream, gut bacteria composition, body composition, as well as any relationship of these substances with markers of inflammation.

    ✓ Study care freeEarly Phase 1Ages 18–60Learn more →
  • Obesity / overweight

    AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

    Testing an injection treatment once a week for people with obesity to help maintain weight loss

    📍 Pinnacle Research Group LLC · Anniston, AL · +12 more US sites · Get directions →

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Obesity / overweightCrohn's / ulcerative colitis (IBD)

    Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

    Testing two medicines together to reduce ulcerative colitis symptoms and weight in adults with

    📍 Digestive Health Specialists · Dothan, AL · +36 more US sites · Get directions →

    The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Obesity / overweightCrohn's / ulcerative colitis (IBD)

    Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    Testing treatments for adults with Crohn’s disease and excess weight

    📍 Digestive Health Specialists · Dothan, AL · +34 more US sites · Get directions →

    The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Obesity / overweightHigh blood pressure

    Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

    Testing whether angiotensin-(1-7) affects heart health in people with obesity and high blood

    📍 Penn State Milton S. Hershey Medical Center · Hershey, PA · Get directions →

    Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

    ✓ Study care freeEarly Phase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis

    📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →

    The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Obesity / overweight

    AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Testing injections once a week to help adults with obesity and type 2 diabetes lose weight

    📍 Univ of Alabama Birmingham · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweight

    A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Testing how well CagriSema and cagrilintide help children with obesity lose weight

    📍 Neighborhood Healthcare · Escondido, CA · +33 more US sites · Get directions →

    This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.

    ✓ Study care freePhase 3Ages 8–18Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweight

    Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

    Testing a once-weekly under-the-skin injection for weight loss in adults with obesity or overweight

    📍 Kailera Clinical Site · Anniston, AL · +22 more US sites · Get directions →

    The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweight

    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Testing tirzepatide with healthy diet and exercise for teens with obesity

    📍 Children's Hospital Los Angeles · Los Angeles, CA · +13 more US sites · Get directions →

    The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.

    ✓ Study care freePhase 3Ages 12–17Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Parkinson's disease

    Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

    Studying how a brain imaging tracer binds in early Parkinson’s over 24 months

    📍 UAB · Birmingham, AL · Get directions →

    The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.

    ✓ Study care freeEarly Phase 1Ages 18–99Learn more →
  • Obesity / overweight

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Testing retatrutide to help people with obesity and chronic low back pain

    📍 MD First Research - Chandler · Chandler, AZ · +24 more US sites · Get directions →

    The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Obesity / overweightType 2 diabetes

    A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    Testing different doses of CagriSema and semaglutide for weight loss in people with obesity, with or

    📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Showing the first 60 of 121. Add filters or a location to narrow down.